このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

手術のための FVIII 治療が必要な血友病の女性/少女の管理における Nuwiq の投与量と結果

2026年11月11日 更新者:Octapharma

手術のために第 VIII 因子治療が必要な血友病の女性/少女の管理における Nuwiq の投与量と結果 - 国際非盲検非対照研究 (NuDIMENSION)

Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment

研究の種類

介入

入学 (推定)

28

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Texas
      • San Antonio、Texas、アメリカ、78229
        • 募集
        • UT Health San Antonio
      • Leeds、イギリス
        • 募集
        • St. James's University Hospital
      • Catanzaro、イタリア
        • 募集
        • Aziendo Ospedaliera "Puglieze Ciaccio"
      • Palermo、イタリア
        • 募集
        • Policlinico "P. Giaconne"
    • Trentino-Alto Adige
      • Trento、Trentino-Alto Adige、イタリア
        • 募集
        • Santa Chiara Hospital - APSS
      • Montevideo、ウルグアイ
        • まだ募集していません
        • Centro Hospitalario Pereira Rossell
      • Bern、スイス
        • 募集
        • Insel Spital Bern
      • Madrid、スペイン
        • 募集
        • Hospital Universitario la Paz
      • Seville、スペイン
        • 募集
        • Hospital Universitario Virgen del Rocio
      • Belgrade、セルビア
        • 募集
        • Clinical Center for Serbia
      • Bonn、ドイツ
        • 募集
        • Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin
      • Duisburg、ドイツ
        • 募集
        • Gerinnungszentrum Rhein-Ruhr
      • Hamburg、ドイツ
        • 募集
        • Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik
      • Helsinki、フィンランド
        • 募集
        • Helsinki University Hospital,Coagulation Disorder Unit
      • Chambray-lès-Tours、フランス
        • 募集
        • Avenue de la République
      • Nantes、フランス
        • 募集
        • CHU de Nantes Hôtel-Dieu
      • Strasbourg、フランス
        • 募集
        • Chu de Strasbourg

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Women/girls with haemophilia A (FVIII:C ≥1-<40%) according to medical history. Additionally, women/girls with documented FVIII activity levels between ≥ 40% and 50% may be included if there is a documented history of clinically significant bleeding episodes consistent with haemophilia A; and/or either documented prior treatment with FVIII concentrates or a clinical indication that FVIII treatment would have been appropriate (e.g., use of FVIII from a family member, or treatment with alternative haemostatic agents due to access limitations)
  2. At least 12 years of age
  3. Scheduled to undergo major surgery* requiring FVIII treatment, including elective and emergency procedures and caesarean section in pregnant women with haemophilia A
  4. Freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations

Exclusion Criteria:

  1. Coagulation disorder other than haemophilia A
  2. Present or past FVIII inhibitor (≥0.6 Bethesda units [BU]/mL)
  3. Severe liver or kidney disease (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels >5 times the upper limit of normal; or creatinine >120 μmol/L)
  4. Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
  5. Pregnancy, except in participants with a planned caesarean section
  6. Already had surgery in this study
  7. Current participation in another interventional clinical trial
  8. Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Nuwiq

All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.

Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall haemostatic efficacy
時間枠:During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

Overall haemostatic efficacy of treatment measured as binary "success" or "failure". The overall perioperative haemostatic efficacy of Nuwiq will be adjudicated by an Independent Data Monitoring Committee (IDMC) and determined using a composite assessment algorithm that considers the surgeon's assessment of intraoperative haemostatic efficacy and the investigator's assessment of postoperative haemostatic efficacy to classify the overall haemostatic efficacy as success or failure.

During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

二次結果の測定

結果測定
メジャーの説明
時間枠
Intraoperative haemostatic efficacy
時間枠:During surgery: From first skin incision to last suture

Assessment of intraoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale:

Excellent: Intraoperative blood loss was lower than or equal to the average expected blood loss for the type of procedure performed in a patient with normal haemostasis and of the same sex, age, and stature

Good: Intraoperative blood loss was higher than the average expected blood loss but lower or equal to the maximal expected blood loss for the type of procedure in a patient with normal haemostasis.

Moderate: Intraoperative blood loss was higher than the maximum expected blood loss for the type of procedure performed in a patient with normal haemostasis, but haemostasis was controlled.

None: Haemostasis was uncontrolled, necessitating a change in the clotting factor replacement regimen.

During surgery: From first skin incision to last suture
Postoperative haemostatic efficacy
時間枠:During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

Assessment of postoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale:

Excellent: No postoperative bleeding or oozing that was not due to complications of surgery. All postoperative bleeding (due to complications of surgery) was controlled with Nuwiq as anticipated for the type of procedure.

Good: No postoperative bleeding or oozing that was not due to complications of surgery. Control of postoperative bleeding due to complications of surgery required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure.

Moderate: Some postoperative bleeding and oozing that was not due to complications of surgery. Control of postoperative bleeding required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure.

None: Extensive uncontrolled postoperative bleeding and oozing.

During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
Allogenic blood products
時間枠:During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

Use of allogeneic blood products (red blood cells, platelets, and other blood products)

During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
FVIII plasma levels
時間枠:≤30 minutes before and 15-30 minutes after Nuwiq injection

Perioperative plasma levels

≤30 minutes before and 15-30 minutes after Nuwiq injection
Perioperative haemostatic efficacy per WFH criteria
時間枠:≤30 minutes before and 15-30 minutes after Nuwiq injection

Assessed using 4-point scale recommended by WFH:

Excellent: Intra- and post-operative blood loss similar to non-haemophilic patient. No extra doses of FVIII/bypassing agents needed Good: Intra- and/or post-operative blood loss slightly increased over expectation for non-haemophilic patient, but judged to be clinically insignificant. No extra doses of FVIII/bypassing agents needed Fair: Intra- and/or post-operative blood loss increased over expectation for the non-haemophilic patient, and additional treatment needed. Extra dose of FVIII/bypassing agents needed, or increased blood component of anticipated transfusion requirement Poor: Significant intra- and/or post-operative blood loss substantially increased over expectation for non-haemophilic patient, requires intervention not explained by medical issue other than haemophilia. Unexpected hypotension, unexpected transfer to ICU due to bleeding, substantially increased blood component of the anticipated transfusion requirement

≤30 minutes before and 15-30 minutes after Nuwiq injection
Adverse events
時間枠:From start of first Nuwiq injection to 30 ±3 days following the surgical procedure

Incidence of adverse events recorded during the full study period

From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
Thrombotic events
時間枠:From start of first Nuwiq injection to 30 ±3 days following the surgical procedure

Incidence of thrombotic events during the study

From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
FVIII inhibitor formation
時間枠:From start of first Nuwiq injection to 30 ±3 days following the surgical procedure

Incidence of FVIII inhibitor formation

From start of first Nuwiq injection to 30 ±3 days following the surgical procedure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Johannes Oldenburg、Experimental Haematology and Transfusion Medicine, University Clinic Bonn

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月12日

一次修了 (推定)

2027年2月1日

研究の完了 (推定)

2027年2月1日

試験登録日

最初に提出

2023年6月8日

QC基準を満たした最初の提出物

2023年7月3日

最初の投稿 (実際)

2023年7月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する